| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bf0ceab440a28b91d70922a4623b1ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ac95eb5d30715d6b58894c19604b97d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da5ac784fcbb213313bda68dda9907b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ccdf9a381e1173c6fa395799b686681b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17b67e154e0fd3c55525187919eeacc4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
1990-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35b7388c0553041b2fb6093dad7fe461
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e30b0e605cd1e4bd1f6b391053ed436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99dfed8b25e078dc7d080b9d8304b073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71ebf4af8796d3366b376b6b3702a812 |
| publicationDate |
1992-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0486609-A1 |
| titleOfInvention |
PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF SEPTICEMIA. |
| abstract |
An antibody to tumor necrosis factor alpha (anti-FNT) and an antibody to bacterial lipopolysaccharide (anti-LPS) have been shown to work together in a murine neutropenic model of sepsis, increasing the survival of rats compared to to either of the antibodies used alone. Pharmaceuticals comprising each of the components are therefore useful in the therapy of sepsis. The anti-LPS antibody included may be specific to the specific O chain of a particular bacterial lipopolysaccharide (antibody specific to the serotype), but it preferably recognizes the central glycolipid of the lipopolysaccharide. |
| priorityDate |
1989-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |